利用基因组和转录组,优化结直肠癌精准医疗(综述)
创作:orchid 审核:周旸 01月06日
  • 基因组和转录组测序、基因编辑、互作通路分析和机器学习技术的联用,可为结直肠癌(CRC)诊断、个体化药物反应预测等精准医疗提供高质量的循证医学证据;
  • 各种类型的二代测序和CRISPR-Cas技术,为阐释原发性和转移性肿瘤内基因组和转录异质性提供指导;
  • DNA和RNA编辑技术有助于推动发现新的CRC治疗靶标;
  • 前沿技术的联用,可以克服缺乏CRC晚期诊断手段、缺乏可靠的预后预测生物标志物以及缺乏新药物靶向这三个挑战。
主编推荐语
周旸
本综述讨论了结直肠癌相关基因组、转录组研究进展和临床转化,系统性介绍了科研数据和技术在结直肠癌诊断、用药选择、复发预测等方面的运用,指出需要进一步挖掘转录水平的关键因子,作为今后精准治疗结直肠癌的指导手段。本文有助于了解结直肠癌治疗的前沿进展,值得参考。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Comprehensive intra-individual genomic and transcriptional heterogeneity: evidence-based Colorectal Cancer Precision Medicine

全面分析个体基因组和转录组异质性:基于循证的结直肠癌精准医疗(综述)

10.1016/j.ctrv.2019.101894

2019-09-03, Review

Abstract & Authors:展开

Abstract:收起
Despite advances in translating conventional research into multi-modal treatment for colorectal cancer (CRC), therapeutic resistance and relapse remain unresolved in advanced resectable and, particularly, non-resectable disease. Genome and transcriptome sequencing and editing technologies, coupled with interaction mapping and machine learning, are transforming biomedical research, representing the most rational hope to overcome unmet research and clinical challenges. Rapid progress in both bulk and single-cell next-generation sequencing (NGS) analyses in the identification of primary and metastatic intratumor genomic and transcriptional heterogeneity (ITH) and the detection of circulating cell-free DNA (cfDNA) alterations is providing critical insight into the origins and spatiotemporal evolution of genomic clones responsible for early and late therapeutic resistance and relapse. Moreover, DNA and RNA editing pave new avenues towards the discovery of novel drug targets. Breakthrough combinations of sequencing and editing systems with technologies exploring dynamic interaction networks within pioneering studies could delineate how coding and non-coding mutations perturb regulatory networks and gene expression. This review discusses latest data on genomic and transcriptomic landscapes in time and space, as well as early-phase clinical trials on targeted drug combinations, highlighting the transition from research to clinical Colorectal Cancer Precision Medicine, through non-invasive screening, individualized drug response prediction and development of multiple novel drugs. Future studies exploring the potential to target key transcriptional drivers and regulators will contribute to the next-generation pharmaceutical controllability of multi-layered aberrant transcriptional biocircuits.

First Authors:
Ioannis D Kyrochristos

Correspondence Authors:
Dimitrios H Roukos

All Authors:
Ioannis D Kyrochristos,Dimitrios H Roukos

评论